6-氟-3-(哌啶-4-基)苯并[D]异恶唑 | 84163-77-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 中文名称: 6-氟-3-(哌啶-4-基)苯并[D]异恶唑
• 中文别名: 6-氟-3-(4-哌啶基)-1,2苯併异噁唑；6-氟-3-(4-哌啶基)-1,2-苯异恶唑；6-氟-3-(4-哌啶基)-1,2-苯并异唑；6-氟-3-(4-哌啶基)-1,2苯并异唑；6-氟-3-(4-哌啶基)-1,2苯并异噁唑；6-氟-3-(4-哌啶基)-1,2 苯并异唑
• 英文名称: 4-(6-fluorobenzisoxazol-3-yl)piperidine
• 英文别名: 6-fluoro-3-(4-piperidinyl)benzo[d]isoxazole；6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole；6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole；6-fluoro-3-piperidin-4-yl-1,2-benzoxazole
• CAS: 84163-77-9
• 化学式: C₁₂H₁₃FN₂O
• mdl: MFCD03236724
• 分子量: 220.246
• InChiKey: MRMGJMGHPJZSAE-UHFFFAOYSA-N

物化性质

• 熔点：
  59-62°C
• 沸点：
  359.0±42.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  4

ADMET

代谢

6-氟-3-(4-哌啶基)-1,2-苯并异噁唑是利培酮的一个已知人体代谢物。

6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole is a known human metabolite of risperidone.

来源:NORMAN Suspect List Exchange

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• RTECS号：
  DL6425000
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 危险标志：
  GHS06
• 危险性描述：
  H301,H315,H319,H335
• 危险性防范说明：
  P261,P301 + P310,P305 + P351 + P338
• 储存条件：
  -20°C 冰箱

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 6-Fluoro-3-(4-Piperidinyl)-1,2-Benzisoxazole
: CDS003236
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 220,25 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
6-Fluoro-3-(4-Piperidinyl)-1,2-Benzisoxazole
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
6-Fluoro-3-(4-Piperidinyl)-1,2-Benzisoxazole
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (6-Fluoro-3-(4-Piperidinyl)-1,2-Benzisoxazole)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (6-Fluoro-3-(4-Piperidinyl)-1,2-Benzisoxazole)
IATA: Toxic solid, organic, n.o.s. (6-Fluoro-3-(4-Piperidinyl)-1,2-Benzisoxazole)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

齐拉西酮中间体。

用途简介

反应信息

• 作为反应物：
  描述：

  6-氟-3-(哌啶-4-基)苯并[D]异恶唑 在 lithium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 125.0~180.0 ℃ 、4.5 MPa 条件下， 生成 伊潘立酮
  参考文献：
  名称：

  热水中的流合成：非典型抗精神病药物伊潘立酮的合成

  摘要：

  感应加热的钢反应堆利用亚临界条件下水的独特物理化学特性，在高温条件下连续地在水中进行有机转化。我们在非典型抗精神病药物伊潘立酮的连续合成中证明了这种设置的威力，其中我们在水性条件下进行了五分之四的步骤。

  DOI：

  10.1002/chem.201504409
• 作为产物：
  描述：

  1,3-二氟苯 在 盐酸 、 aluminum (III) chloride 、 盐酸羟胺 、 potassium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 13.0h， 生成 6-氟-3-(哌啶-4-基)苯并[D]异恶唑
  参考文献：
  名称：

  一种6-氟-3-（4-哌啶基）-1,2-苯并异噁唑盐酸盐的纯化方法

  摘要：

  本发明公开一种利培酮中间体如式II所示的6‑氟‑3‑(4‑哌啶基)‑1,2‑苯并异噁唑盐酸盐的纯化方法，其特征在于，所述的纯化方法是将6‑氟‑3‑(4‑哌啶基)‑1,2‑苯并异噁唑盐酸盐加入到乙醇中，再加入一定量的水，加热回流至溶清，降温至一定温度进行养晶，然后再降温至‑5～10℃，过滤，烘干得到。本发明提供的6‑氟‑3‑(4‑哌啶基)‑1,2‑苯并异噁唑盐酸盐的纯化方法，能有效地将式Ⅴ二聚体分离出去，纯化收率在85％以上，成品的化学纯度可达到99.9％以上，并且在大生产中不会产生放大效应，工艺稳定。

  公开号：

  CN112624992A
• 作为试剂：
  描述：

  6-氟-3-(哌啶-4-基)苯并[D]异恶唑 、 7-(3-chloropropoxy)-3-(hydroxymethyl)chromen-4-one 在 6-氟-3-(哌啶-4-基)苯并[D]异恶唑 作用下， 以37的产率得到阿巴哌酮
  参考文献：
  名称：

  J. Med. Chem. 1996, 39, 2962-2970

  摘要：

  DOI：

文献信息

• Access to Aryl and Heteroaryl Trifluoromethyl Ketones from Aryl Bromides and Fluorosulfates with Stoichiometric CO
  作者：Martin B. Johansen、Oliver R. Gedde、Thea S. Mayer、Troels Skrydstrup

  DOI：10.1021/acs.orglett.0c01117

  日期：2020.6.5

  trifluoromethyl ketones starting from readily accessible aryl bromides and fluorosulfates, the latter easily prepared from the corresponding phenols. The methodology utilizes low pressure carbon monoxide generated ex situ from COgen to generate Weinreb amides as reactive intermediates that undergo monotrifluoromethylation affording the corresponding aromatic trifluoromethyl ketones (TFMKs) in good

  我们报告了从容易获得的芳基溴化物和氟代硫酸盐开始的顺序一锅法制备芳族三氟甲基酮的方法，后者很容易从相应的苯酚制备。该方法利用产生低压一氧化碳易地从热电联产产生的Weinreb酰胺作为经历monotrifluoromethylation得到良好的收率的相应的芳族三氟甲基酮（TFMKs）的活性中间体。通过化学计量使用CO，可以通过切换使用13 COgen来访问13 C同位素标记的TFMK。
• [EN] NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 2-PIPERIDIN-1-YL-ACETAMIDE UTILISABLES EN TANT QU'INHIBITEURS DE TANKYRASE
  申请人：NOVARTIS AG

  公开号：WO2013012723A1

  公开（公告）日：2013-01-24

  The present invention provides for compounds of formula (I), wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

  本发明提供了式(I)的化合物，其中R1-R5和L在此处定义。本发明还提供了包含式(I)化合物的药物组合物和组合物，以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途，包括但不限于癌症。
• 1,2-benzisoxazole compounds
  申请人：Adir et Compagnie

  公开号：US05100902A1

  公开（公告）日：1992-03-31

  Compounds of formula I ##STR1## in which m represents an integer from 0 to 5, n represents an integer from 1 to 2, p is equal to 0, 1 or 2, X, Y and Z, which may be identical or different, each represent a hydrogen atom, a halogen atom, a linear or branched alkyl radical, a trifluoromethyl radical, an alkoxy radical, an alkylthio radical or a hydroxyl radical, and R represents a 2-benzofuranyl or 2,3-dihydro-2-benzofuranyl radical (it being possible for each to be substituted on the benzene ring), a 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-2-yl radical, a 4-oxo-4H-chromen-2-yl radical (optionally substituted on the benzene ring), a benzocyclobutenyl radical of formula A or an indanyl radical of formula B: ##STR2## (in which: R.sub.1 and R.sub.2, which may be identical or different, each represent a hydrogen atom, a halogen atom, a trifluoromethyl radical, an alkyl radical, an alkoxy radical, a hydroxyl radical, a hydroxyalkyl radical or an alkylthio radical, or together form a methylenedioxy radical or an ethylenedioxy radical, and R.sub.3 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms), or a radical of formula C: ##STR3## (in which R.sub.4, R.sub.5 and R.sub.6, which may be identical or different, each represent a hydrogen atom, a halogen atom, a trifluoromethyl radical, a hydroxyl radical, an alkyl radical, an alkoxy radical or an alkylthio radical, their optical isomers and their addition salts with a pharmaceutically acceptable organic or inorganic acid.

  式I的化合物##STR1##中，其中m表示0到5的整数，n表示1到2的整数，p等于0、1或2，X、Y和Z，可以相同也可以不同，每个代表氢原子、卤素原子、直链或支链烷基基团、三氟甲基基团、烷氧基团、烷基硫基团或羟基基团，而R代表2-苯并呋喃基或2,3-二氢-2-苯并呋喃基（每个都可以在苯环上被取代），2,3,6,7-四氢苯并[1,2-b:4,5-b']二呋喃-2-基基团，4-氧代-4H-香豆素-2-基基团（在苯环上可选择取代），A式苯并环丁烯基基团或B式茚基基团：##STR2##（其中：R.sub.1和R.sub.2，可以相同也可以不同，每个代表氢原子、卤素原子、三氟甲基基团、烷基基团、烷氧基团、羟基基团、羟基烷基基团或烷基硫基团，或者一起形成亚甲二氧基基团或乙烯二氧基基团，而R.sub.3代表氢原子或具有1到6个碳原子的直链或支链烷基基团），或C式基团：##STR3##（其中R.sub.4、R.sub.5和R.sub.6，可以相同也可以不同，每个代表氢原子、卤素原子、三氟甲基基团、羟基基团、烷基基团、烷氧基团或烷基硫基团，它们的光学异构体及其与药学上可接受的有机或无机酸的加合盐。
• Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics
  作者：Ling Huang、Lanchang Gao、Xiaohua Zhang、Lei Yin、Jintao Hu、Ting Song、Yin Chen

  DOI：10.1016/j.bmcl.2020.127506

  日期：2020.10

  We report the optimisation of a series of novel amide-piperidine (piperazine) derivatives using the multiple ligand approach with dopamine and serotonin receptors. Of the derivatives, compound 11 exhibited high affinity for the D2, 5-HT1A, and 5-HT2A receptors, but low affinity for the 5-HT2C and histamine H1 receptors and human ether-a-go-go-related gene (hERG) channels. In vivo, compound 11 reduced

  我们报告了与多巴胺和5-羟色胺受体的多配体方法一系列新型酰胺-哌啶（哌嗪）衍生物的优化。在衍生物中，化合物11显示出高亲和力为d 2，5-HT 1A和5-HT 2A受体，但低亲和性对5-HT 2C和组胺H 2 1受体和人ether-A-GO-中间人相关基因（hERG）通道。体内化合物11即使在测试的最高剂量下，阿扑吗啡引起的攀爬，MK-801引起的活动过度和DOI引起的头部抽搐也没有明显的僵直。另外，它在CAR测试中表现出抑制作用。此外，在一个新颖的物体识别任务中，它显示了识别属性。因此，化合物11是有希望的候选多靶点抗精神病药。
• Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics
  作者：Lanchang Gao、Zhengge Yang、Jiaying Xiong、Chao Hao、Ru Ma、Xin Liu、Bi-Feng Liu、Jian Jin、Guisen Zhang、Yin Chen

  DOI：10.3390/molecules25184107

  日期：——

  was also endowed with low to moderate activities on 5-HT2C, α1, and H1 receptors, indicating a low liability to induce side effects such as weight gain, orthostatic hypotension and QT prolongation. In vivo behavioral studies suggested that 6j has favorable effects in alleviating the schizophrenia-like symptoms without causing catalepsy. Taken together, compound 6j has the potential to be further developed

  通过使用多巴胺受体和血清素受体之间的多受体亲和策略，设计了一系列新型黄酮衍生物作为潜在的广谱抗精神病药。其中，7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl) piperidin-1-yl) butoxy)-2,2-dimethylchroman-4-one (6j) 表现出有希望的临床前特征. 化合物 6j 不仅对多巴胺 D2、D3 和血清素 5-HT1A、5-HT2A 受体表现出高亲和力，而且对 5-HT2C、α1 和 H1 受体也具有低至中度的活性，表明诱导的可能性较低副作用如体重增加、体位性低血压和 QT 间期延长。体内行为研究表明，6j 在减轻精神分裂症样症状方面具有良好的作用，而不会引起僵住症。综合起来，